Year: 2026
Type: article
Abstract: Artificial Intelligence (AI) is revolutionizing drug discovery and development by improving speed, accuracy, and cost-effectiveness. It plays a vital role in target identification and validation using genomic, proteomic, and bioinformatics tools, enabling precision medicine. AI-driven techniques such as machine learning and deep learning enhance virtual screening, allowing rapid identification of potential drug candidates from large chemical libraries. Generative models and reinforcement learning support de novo drug design and lead optimization, improving efficacy, selectivity, and safety. Additionally, AI-based ADMET prediction helps assess pharmacokinetic and toxicity profiles early, reducing late-stage failures and experimental costs. AI also contributes to pharmacovigilance through real-time adverse event detection. However, challenges such as data quality issues, lack of interpretability, regulatory barriers, and ethical concerns remain. Overall, AI holds significant potential to accelerate drug development and deliver safer, more effective therapies.
Language: English
Subfield: Drug Discovery
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W7163359137
